bempedoic acid
- Generic Name
- bempedoic acid
- Brand Names
- Nexletol, Nexlizet, Nilemdo
- Drug Type
- Small Molecule
- Chemical Formula
- C19H36O5
- CAS Number
- 738606-46-7
- Unique Ingredient Identifier
- 1EJ6Z6Q368
- Background
High levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events. Caused by genetic mutations or lifestyle factors, hypercholesterolemia can significantly reduce quality of life and increase the risk of mortality from cardiovascular disease. About 1 in 4 patients, or 15 million Americans with elevated LDL-C, are insufficiently managed...
- Indication
作为饮食和最大耐受性他汀类药物治疗的辅助药物，用于治疗患有杂合子家族性高胆固醇血症或需要额外降低LDL-C的动脉粥样硬化性心血管疾病的成人。
- Associated Conditions
- Atherosclerotic Cardiovascular Diseases, Heterozygous Familial Hypercholesterolemia (HeFH)
- Associated Therapies
- -
ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada
Esperion Therapeutics filed NDSs in Canada for Nexletol and Nexlizet to reduce LDL-C and cardiovascular risk. Nexlizet combines bempedoic acid and ezetimibe. Shares rose 10.7% post-announcement. The drugs are approved in the U.S. and Europe, marketed as Nilemdo and Nustendi ex-U.S. (excluding Japan). Label expansions in 2024 support broader use, with net product sales up 46.2% YOY in 2024. Otsuka Pharmaceutical filed for bempedoic acid in Japan, potentially boosting future sales.
Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid ...)
Esperion files New Drug Submissions to Health Canada for NEXLETOL and NEXLIZET, once-daily, oral non-statin medications reducing LDL-C and cardiovascular risk, aiming to address heart disease, the leading global cause of death.
Esperion Therapeutics, Inc. SEC 10-Q Report
Esperion Therapeutics reports $31.1M in product sales, $20.5M in collaboration revenue, and a net loss of $29.5M. The company focuses on oral, non-statin medicines for cardiovascular disease, with lead products NEXLETOL and NEXLIZET. Regulatory approvals and clinical trial results support product efficacy. Strategic initiatives include a royalty purchase agreement and capital management. Challenges include financial performance, market competition, and regulatory risks.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath